Researchers have developed a drug that blocks HIV from inserting its genome into the DNA of the host cells - known by researchers as the point of no return. The treatment targets integrase, an enzyme essential for viral replication that doesn't exist in humans, which means there's a low risk of side effects. The therapy is now in the pre-clinical testing phase.